Immunoprecise Antibodies Ltd Stock Other OTC
Stocks
CA87588T1030
Pharmaceuticals
| Market Cap | 86.16M 62.49M 53.77M 50.46M 46.16M 5.91B 86.85M 597M 232M 3.02B 235M 230M 9.72B | P/E 2027 * |
-5.98x | P/E 2028 * | -7.82x |
|---|---|---|---|---|---|
| Enterprise Value | 86.16M 62.49M 53.77M 50.46M 46.16M 5.91B 86.85M 597M 232M 3.02B 235M 230M 9.72B | EV / Sales 2027 * |
4.26x | EV / Sales 2028 * | 3.46x |
| Free-Float |
90.86% | Yield 2027 * |
-
| Yield 2028 * | - |
Last Transcript : Immunoprecise Antibodies Ltd
| 1 day | -6.29% |
| Manager | Title | Age | Since |
|---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 2018-02-20 |
Richard Areglado
DFI | Director of Finance/CFO | 62 | 2025-10-19 |
Hyfte Van
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Jennifer Bath
BRD | Director/Board Member | - | 2018-05-23 |
Dirk Witters
CHM | Chairman | - | - |
Jonathan Lieber
BRD | Director/Board Member | 56 | 2025-07-06 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.29% | -23.22% | - | - | 62.73M | |
| -1.00% | +4.43% | +49.60% | +1.42% | 85.08B | |
| -1.29% | +4.27% | +519.00% | +32.26% | 60.21B | |
| -0.26% | +1.56% | -17.00% | -34.81% | 59.71B | |
| -1.60% | -7.34% | -5.08% | +31.05% | 51.1B | |
| +0.09% | -0.54% | +9.26% | +165.71% | 48.73B | |
| +0.83% | +1.36% | +58.53% | -15.97% | 32.9B | |
| -0.64% | +0.20% | +47.19% | +97.87% | 26.11B | |
| +0.79% | -4.65% | -4.11% | +192.31% | 22.6B | |
| +1.10% | -1.67% | +64.17% | +118.01% | 16.42B | |
| Average | -0.83% | -0.26% | +80.17% | +65.32% | 44.76B | |
| Weighted average by Cap. | -0.52% | +0.72% | +96.22% | +44.59% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 20.24M 14.68M 12.63M 11.86M 10.85M 1.39B 20.41M 140M 54.62M 709M 55.14M 53.94M 2.28B | 24.9M 18.06M 15.54M 14.58M 13.34M 1.71B 25.09M 172M 67.17M 872M 67.81M 66.33M 2.81B |
| Net income | -14.81M -10.74M -9.24M -8.67M -7.94M -1.02B -14.93M -103M -39.96M -519M -40.34M -39.46M -1.67B | -11.81M -8.56M -7.37M -6.91M -6.33M -809M -11.9M -81.78M -31.85M -414M -32.15M -31.45M -1.33B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
